The LAM Foundation

The LAM Foundation catalyzes new treatments—and ultimately a cure—for LAM by advancing research, supporting compassionate care, and amplifying the voice of women with rare diseases.

Lymphangioleiomyomatosis (LAM) is a rare and progressive lung disease that primarily affects women and has no known cure. Founded in 1995 as a grassroots effort, The LAM Foundation is the global leader in the fight against LAM. It has evolved into an organization that is described by the National Heart, Lung, and Blood Institute (NHLBI) as “a model for voluntary health agencies.”

The LAM Foundation provides support and education for women with LAM and their families, engages doctors and scientists to continue to learn more about the disease, and raises funds for continued research. In May 2015, the FDA approved Rapamune as the first effective treatment for LAM, based on research and patient engagement supported by The LAM Foundation.